Read More Pharma Industry News Can Gujarat Themis Biosyn turn a Japanese acquisition into a global CDMO platform? Gujarat Themis Biosyn is buying MicroBiopharm Japan for ₹1,300 crore. Find out why this CDMO bet matters for #GUJTHEM today! byPallavi MadhirajuMay 25, 2026